NM_004004.6:c.35G>A
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM5PP3_Strong
The NM_004004.6(GJB2):c.35G>A(p.Gly12Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000022 in 1,591,136 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G12V) has been classified as Pathogenic.
Frequency
Consequence
NM_004004.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000133 AC: 2AN: 150236Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000722 AC: 18AN: 249434Hom.: 1 AF XY: 0.0000593 AC XY: 8AN XY: 135006
GnomAD4 exome AF: 0.0000229 AC: 33AN: 1440900Hom.: 1 Cov.: 32 AF XY: 0.0000251 AC XY: 18AN XY: 717000
GnomAD4 genome AF: 0.0000133 AC: 2AN: 150236Hom.: 0 Cov.: 32 AF XY: 0.0000272 AC XY: 2AN XY: 73440
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 12 of the GJB2 protein (p.Gly12Asp). This variant is present in population databases (rs1801002, gnomAD 0.03%). This missense change has been observed in individual(s) with deafness (PMID: 21388256, 22695344, 24774219, 25012701). ClinVar contains an entry for this variant (Variation ID: 551229). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt GJB2 protein function with a positive predictive value of 95%. This variant disrupts the p.Gly12 amino acid residue in GJB2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10982180, 19371219, 24158611, 25288386). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Reported in multiple individuals with hearing loss in published literature; however, some individuals were reported to harbor this variant as a single heterozygous variant despite family history suggestive of recessive inheritance, and others did not provide zygosity or the presence of a second variant (Ferraris et al., 2002; Mahdieh et al., 2011; Bazazzadegan et al., 2012; Loeza-Becerra et al., 2014; Hernandez-Juarez et al., 2014; Zeinali et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 12325027, 25388846, 25288386, 22695344, 24774219, 25012701, 26252218, 21388256, 31215297, 34276761, 35457072) -
not specified Uncertain:1
Variant summary: GJB2 c.35G>A (p.Gly12Asp) results in a non-conservative amino acid change located in the Connexin, N-terminal domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7.2e-05 in 249434 control chromosomes in the gnomAD database, including 1 homozygotes. This frequency is not significantly higher than expected for a pathogenic variant in GJB2 causing Non-Syndromic Hearing Loss (7.2e-05 vs 0.00034), allowing no conclusion about variant significance. c.35G>A has been reported in the literature in individuals affected with Hearing Loss in heterozygous state (Ferraris_2002, Mahdieh_2011, Bazazzadegan_2012, Loeza-Becerra_2014, Hernandez-Juarez_2014, Gruber_2016). These reports do not provide unequivocal conclusions about association of the variant with Autosomal Recessive Non-Syndromic Hearing Loss. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely pathogenic, and one laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -
Autosomal recessive nonsyndromic hearing loss 1A Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at